Contribution of APOA5 gene variants to plasma triglyceride determination and to the response to both fat and glucose tolerance challenges  by Martin, Steve et al.
www.bba-direct.com
Biochimica et Biophysica Acta 1637 (2003) 217–225Contribution of APOA5 gene variants to plasma triglyceride determination
and to the response to both fat and glucose tolerance challenges
On behalf of the EARS group
Steve Martina, Viviane Nicaudb, Steve E. Humphriesa, Philippa J. Talmuda,*
aDivision of Cardiovascular Genetics, Department of Medicine, British Heart Foundation Laboratories, Rayne Building,
Royal Free and University College Medical School, 5 University Street, London WC1E 6JF, UK
bFaculte de Medecine Pitie-Salpetriere, INSERM U525, 91 Boulevard de l’ Hopital, 75634 Paris cedex 13, FranceReceived 6 January 2003; received in revised form 26 February 2003; accepted 26 February 2003Abstract
The aim of this study was to investigate the influence of APOA5 variants on fasting lipids and to the response to both an oral fat tolerance
test (OFTT) and an oral glucose tolerance test (OGTT). The association of two APOA5 SNPs [S19W (SNP5),  1131T>C (SNP3)] and an
APOA4/A5 intergenic SNP [ 12238T>C (SNP4)] were examined in healthy young men (n = 774) who had undergone both an OFTT and an
OGTT. Both  1131T>C and S19W rare alleles were associated with triglyceride (TG)-raising effects (11%, P= 0.008; 21% (in cases),
P< 0.026, respectively) and showed additive effects on TG. None of the variants influenced the responsiveness to the OFTT after correcting
for baseline TG. Homozygosity for the  12238T>C rare allele was associated with higher waist to hip ratio (P < 0.0006), systolic blood
pressure (P= 0.012) and AUC and peak of insulin after OGTT (P= 0.003 and P= 0.027, respectively), traits that define the metabolic
syndrome. Our results strongly support the role of APOA5 in determining plasma TG levels in an age-independent manner and highlight the
importance of the APOC3/A4/A5 gene cluster in both TG and metabolic homeostasis.D 2003 Elsevier Science B.V. All rights reserved.Keywords: APOC3/A4/A5; Plasma triglyceride; Oral fat tolerance test; Oral glucose tolerance test; Offspring study1. Introduction
Results from several studies report that variation in the
newly identified apolipoprotein AV gene (APOA5) influen-
ces plasma triglyceride (TG) levels [1–4]. The genes
comprising the APOA1/C3/A4/A5 cluster all encode apoli-
poproteins involved in lipid metabolism (reviewed in Ref.
[5]) but while APOA1 variants determine apoAI and high
density lipoprotein (HDL) levels, APOC3, APOA4
(reviewed in Ref. [5]) and APOA5 [3,4] show association
with plasma TG levels. Transgenic mouse models identified
that TG levels positively correlate with increased expression
of APOC3 [6], while APOA5 transgenic mice show greatly
reduced TG levels when compared to wild-type mice,
suggesting a different mode of involvement in TG metab-0925-4439/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
doi:10.1016/S0925-4439(03)00033-4
* Corresponding author. Tel.: +44-20-7679-6968; fax: +44-20-7679-
6212.
E-mail address: p.talmud@ucl.ac.uk (P.J. Talmud).olism [1]. ApoCIII inhibits TG-rich lipoprotein (TGRL)
catabolism by inhibition of lipoprotein lipase and displace-
ment of apoE from the particles [6], thus reducing receptor-
mediated clearance. The exact function of apoAV is less
clear, but studies showing the upregulation of apoAV during
liver regeneration after partial rat hepatectomy suggest a role
in the control of TG secretion. APOA4 has inconsistently
been associated with differences in lipid levels (reviewed in
Ref. [5]) although it is known to participate in reverse
cholesterol transport as an activator of lecithin cholesterol
acyl transferase (LCAT) [7] and as a major component of
HDL.
The European Atherosclerosis Study II is a large
multicentre offspring study of over 800 young healthy
men. Those whose fathers had had a myocardial infarct
were designated ‘cases’, while ‘controls’ were drawn at
random from the same university setting [8]. The effects
of two of the genes in the cluster, APOC3 and APOA4,
on fasting lipids and response to the oral fat tolerance test
(OFTT) and oral glucose tolerance test (OGTT) haveed.
Fig. 1. Map of the APOA5 gene on chromosome 11q23 showing the
position of three SNPs under study and the allelic association between them
(* not significant, **P< 0.05, ***P< 0.01).
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that variation within the locus differentially affected the
postprandial response and response to the OGTT. While
the  2854T>G determined the response to a fat load, the
 482C>T, which disrupts the insulin responsive element
in the promoter, was associated with both the glucose and
insulin response to a glucose load [9]. Carriers of the rare
allele of the APOA4 Q360H had significantly reduced
postprandial lipemia but only if they were obese [10].
EARSII provided an opportunity to examine the effects of
APOA5 variants on baseline TGs in healthy young men.
Since this is a large data set with both OFTT and OGTT
responses, this enabled us to examine the effects of
APOA5 genotype on fasting lipid levels as well as post-
prandial clearance of TG and glucose, not examined
previously. In addition, the relative contribution of these
three genes in the cluster to the responses to these chal-
lenges could be assessed.Table 2
Linkage disequilibrium (DV) among nine variants in the APOC3/A4/A52. Methods
2.1. Study population
2.1.1. European Atherosclerosis Research Study II (EARSII)
Participants of the EARSII study, all male and aged
between 18 and 28 years, were divided on the basis of their
father having had a proven myocardial infarction before the
age of 55 years (cases n = 407) and age-matched controls
(n = 415) who were recruited irrespective of family history.
They were recruited from 14 European university student
populations from 11 European countries, which were
divided into four regions: Baltic (Estonia and Finland);
United Kingdom; Middle Europe (Belgium, Denmark, Ger-
many and Switzerland); and South Europe (Greece, Italy,
Portugal and Spain) (for further details, see Ref. [8]). Ethical
approval was obtained from each centre. A standard 75 g
oral glucose load was administered after a 12-h overnight
fast. Venous blood samples were drawn at 0, 30, 60, 90 and
120 min for determination of insulin and glucose concen-
trations. One week later, the participants had an OFTT. The
standard fat meal consisted of 1493 kcal of energy; 21.6 g
dairy milk protein, 56.2 g carbohydrates and 65.5 g dairyTable 1
Rare allele frequencies (95% CI) of the APOA5 S19W,  1131T>C and the
intergenic APOA4/A5  12238T>C variant in the four regions of Europe
participating in EARSII
Region APOA5 S19W APOA5  1131T>C Intergenic APOA4/
A5  12238 T>C*
Baltic 0.07 (0.04, 0.10) 0.08 (0.05, 0.11) 0.30 (0.25, 0.35)
UK 0.04 (0.02, 0.07) 0.08 (0.05, 0.11) 0.35 (0.29, 0.40)
Middle 0.07 (0.05, 0.09) 0.06 (0.04, 0.08) 0.35 (0.31, 0.39)
South 0.07 (0.05, 0.10) 0.08 (0.05, 0.10) 0.41 (0.35, 0.45)
*Difference between regions P= 0.04.milk fat (of which 41.6 g is saturated). The meal was
administered after a 12-h overnight fast. Blood samples
were drawn at 0, 2, 3, 4 and 6 h for determination of TG
concentrations [8].
2.2. DNA genotyping
Genotyping for the S19W,  1131T>C and the APOA5-
A4 intergenic  12238T>C, originally referred to as SNP5,
SNP3 and SNP4, respectively [1], were carried out by
PCR and restriction enzyme digestion as described pre-
viously [3]. All PCRs were performed in a MJ Research
thermal cycler, using Taq polymerase (Amersham, UK).3. Statistical analysis
The database is held on an IBM RISC System/6000 in
Paris and the analyses were performed using the SAS
statistical software (SAS Institute, Cary, NC). Hardy–
Weinberg equilibrium was tested by a v2 test with 2
degrees of freedom separately in cases and controls from
the four European regions described above. Allele fre-locus, using current APOA5 data and that previously published for APOC3
[13] and APOA4 [10]
APOA5 S19W APOA5 
1131T>C
APOA5 A4
intergenic 
12238 T>C
APOC3  2854T>G  0.85*** + 0.68*** + 0.39***
APOC3  482C>T  0.90*** + 0.70*** + 0.27***
APOC3 1100C>T + 0.58*** + 0.52***  0.45***
APOC3 3238C>G  0.55 ns + 0.67***  0.45**
APOA4 T347S  0.64*  0.55* + 0.86***
APOA4 Q360H  1.00 ns  1.00 ns  1.00***
ns: nonsignificant.
*P < 0.05.
**P < 0.01.
***P < 0.001.
Table 3
Baseline characteristics (S.E.) by genotype in EARSII according to case–control status
(a) APOA5  1131T>Ca
Characteristic TT (N= 674) TCa (N= 116) P value genotype
effect
P value for heterogeneity
between cases and controls
BMI (kg/m2)
Cases 23.4 (0.15) 23.2 (0.35) NS NS
Controls 23.2 (0.15) 23.5 (0.38)
Waist/hip ratio
Cases 0.850 (0.002) 0.846 (0.005) NS NS
Controls 0.850 (0.002) 0.855 (0.006)
Systolic BP (mm Hg)
Cases 117.2 (0.6) 119.1 (1.2) NS NS
Controls 117.2 (0.5) 118.5 (1.4)
Diastolic BP (mm Hg)
Cases 73.5 (0.5) 75.9 (1.1) NS 0.091
Controls 73.7 (0.5) 73.0 (1.2)
Cholesterol (mmol/l)
Cases 4.54 (0.05) 4.51 (0.10) NS NS
Controls 4.29 (0.04) 4.33 (0.11)
LDL-C (mmol/l)
Cases 2.91 (0.04) 2.86 (0.09) NS NS
Controls 2.68 (0.04) 2.70 (0.10)
Triglyceride (mmol/l)
Cases 1.00 (0.03) 1.09 (0.06) 0.008 NS
Controls 0.93 (0.03) 1.07 (0.07)
ApoB (g/l)
Cases 73.3 (0.9) 75.3 (2.1) NS NS
Controls 68.5 (0.9) 71.5 (2.3)
HDL-C (mmol/l)
Cases 1.19 (0.01) 1.15 (0.03) 0.073 NS
Controls 1.19 (0.01) 1.14 (0.03)
ApoAI (g/l)
Cases 99.8 (0.9) 101.3 (2.1) NS NS
Controls 100.6 (0.9) 99.5 (2.4)
(b) APOA5 S19W
Characteristic SS (N = 667) SW (N = 98)b P value for
genotype effect
P value for heterogeneity
between cases and controls
BMI (kg/m2)
Cases 23.4 (0.2) 23.1 (0.4) NS NS
Controls 23.2 (0.2) 23.5 (0.4)
Waist/hip ratio
Cases 0.849 (0.002) 0.846 (0.006) NS NS
Controls 0.851 (0.002) 0.851 (0.006)
Systolic BP (mm Hg)
Cases 117.3 (0.5) 118.2 (1.5) NS NS
Controls 117.4 (0.5) 116.8 (1.4)
Diastolic BP (mm Hg)
Cases 73.6 (0.5) 75.0 (1.3) NS NS
Controls 73.8(0.5) 72.7 (1.2)
(continued on next page)
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Table 3 (continued )
(b) APOA5 S19W
Characteristic SS (N= 667) SW (N = 98)b P value for
genotype effect
P value for heterogeneity
between cases and controls
Cholesterol (mmol/l)
Cases 4.54 (0.05) 4.35 (0.12) NS 0.025
Controls 4.26 (0.04) 4.48 (0.11)
LDL-C (mmol/l)
Cases 2.91 (0.04) 2.74 (0.11) NS 0.015
Controls 2.64 (0.04) 2.87 (0.10)
Triglyceride (mmol/l)
Cases 0.98 (0.03) 1.19 (0.07) NS* 0.056
Controls 0.95 (0.03) 0.93 (0.06)
ApoB (g/l)
Cases 73.6 (0.9) 71.4 (2.5) NS NS
Controls 68.4 (0.9) 71.4 (2.5)
HDL-C (mmol/l)
Cases 1.20 (0.01) 1.12 (0.04) NS NS
Controls 1.19 (0.01) 1.18 (0.03)
ApoAI (g/l)
Cases 100.5 (0.9) 95.8 (2.6) NS NS
Control 100.3 (0.9) 101.2 (2.3)
(c) APOA4-A5 intergenic  12238 T>C
Characteristic TT (N = 341) TC (N= 340) CC (N = 110) P value genotype
effect
P value for heterogeneity
between cases and controls
BMI (kg/m2)
Cases 23.6 (0.2) 23.1 (0.2) 23.2 (0.4) 0.094 0.045
Controls 23.1 (0.2) 23.0 (0.2) 24.2 (0.4)
Waist/hip ratio
Cases 0.85 (0.003) 0.85 (0.003) 0.86 (0.006) 0.0006 NS
Controls 0.85 (0.003) 0.85 (0.003) 0.87 (0.006)
Systolic BP (mm Hg)
Cases 116.1 (0.8) 118.3 (0.8) 118.9 (1.3) 0.012 NS
Controls 116.6 (0.7) 117.4 (0.8) 119.8 (1.3)
Diastolic BP (mm Hg)
Cases 73.8 (0.7) 73.5 (0.7) 75.3 (1.2) 0.077 NS
Controls 72.8 (0.7) 73.7 (0.7) 75.6 (1.2)
Cholesterol (mmol/l)
Cases 4.61 (0.06) 4.41 (0.06) 4.62 (0.11) 0.008 NS
Controls 4.36 (0.06) 4.21 (0.06) 4.38 (0.11)
LDL-C (mmol/l)
Cases 2.94 (0.06) 2.79 (0.06) 3.04 (0.10) 0.005 NS
Controls 2.74 (0.06) 2.59 (0.06) 2.77 (0.10)
Triglyceride (mmol/l)
Cases 1.05 (0.04) 0.97 (0.04) 1.01 (0.06) NS NS
Controls 0.95 (0.04) 0.93 (0.04) 0.99 (0.07)
ApoB (g/l)
Cases 74.4 (1.3) 70.9 (1.3) 77.3 (2.2) 0.003 NS
Controls 70.4 (1.2) 66.8 (1.3) 70.5 (2.2)
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(c) APOA4-A5 intergenic  12238 T>C
Characteristic TT (N= 341) TC (N= 340) CC (N= 110) P value genotype
effect
P value for heterogeneity
between cases and controls
HDL-C (mmol/l)
Cases 1.20 (0.02) 1.19 (0.02) 1.14 (0.03) NS NS
Controls 1.19 (0.02) 1.20 (0.02) 1.16 (0.03)
ApoAI (g/l)
Cases 102.1 (1.3) 99.4 (1.3) 95.8 (2.3) NS NS
Controls 100.3 (1.3) 100.7 (1.3) 99.8 (2.3)
a There were no rare homozygotes.
b The sole homozygote WW was pooled with SW carriers.
*P= 0.026 in cases.
Table 3 (continued )
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and the differences between regions and case/control
status examined by a v2 test. Pairwise linkage disequili-
brium coefficients between polymorphisms were esti-
mated using log-linear analysis (A) and their extents
were expressed as the ratio of the unstandardised coef-
ficients to their maximal value ( +D(B.V) [11,12]. Lipid
levels according to genotype were studied by an analysis
of variance (SAS-PROC GLM) adjusted for age, recruit-
ment centre and case/control status. The postprandial
response was compared across genotypes using analysis
of variance (SAS-PROC GLM) for: (a) each time point,
(b) the AUC above the fasting concentration, calculated
by the trapezoidal rule, (c) the peak, calculated as the
highest value minus the fasting value. For distributions
positively skewed, a power transformation (log or square
root) was applied for tests, but untransformed values are
presented in the tables and graphs. Statistical significance
was taken as P < 0.05.Fig. 2. Combined effect of APOA5 S19W and  1131T>C on fasting TG
levels.4. Results
The genotype distributions for all the APOA5 variants
were in Hardy–Weinberg equilibrium and the rare allele
frequencies in the four regions of Europe are presented in
Table 1. There were no differences in frequency among
cases and controls for any of the SNPs. There was some
evidence of heterogeneity among regions for the inter-
genic  12238T>C (P= 0.04) with a frequency gradient
from the North (Baltic region) to the South. The map
position of the two APOA5 SNPs and APOA4-A5
 12238T>C variant and their levels of allelic association
are presented in Fig. 1. S19W showed negative LD with
both  1131T>C and the intergenic  12238T>C SNP;
thus, their rare alleles are on opposite chromosomes. LD
between  1131T>C and the intergenic marker was weak.
The LD across the APOC3/A4/A5 cluster, using previous
genotype information from four APOC3 SNPs [9] and two
APOA4 SNPs [10], together with the APOA5 variants, was
examined (Table 2). There was strong LD betweenAPOA5 variants S19W and  1131T>C and the four
APOC3 variants. The LD coefficients were weaker with
APOA5-A4 intergenic  12238T>C. APOA4 Q360H
showed complete LD with the intergenic  12238T>C
but showed no significant LD with  1131T>C and
S19W, but this reflects the very low rare allele frequencies
of these variants. APOA4 T347S was in significant LD
with all the APOA5 variants.
4.1. Both APOA5 1131T>C and S19W have strong effects
on fasting TG levels
The basic characteristics for relevant traits in subjects
with different genotypes for the APOA5 variants and the
intergenic SNP are presented in Table 3a–c. Both APOA5
 1131T>C and S19W were associated with effects on
fasting TG levels with carriers of the  1131C having
significantly higher plasma TG levels compared to com-
mon allele homozygotes for  1131T (P= 0.008). The
TG-raising effects in carriers of the W19 was seen only
in the ‘cases’ (P= 0.026). These effects of  1131T>C
and S19W were additive and while carriers of either rare
Fig. 3. TG levels after the OFTT by APOA5 S19W (A) and  1131T>C (B) before correction for fasting TG levels in EARSII.
Table 4
Changes in insulin and glucose after the OGTT-mean (S.E.) after correcting
for fasting levels for the APOA4/A5 intergenic  12238T>C SNP
 12238 TT +
TC (N = 681)
 12238CC
(N = 110)
P value
AUC glucose 1.77 (1.0) 2.15 (0.26) 0.037
Peak glucose (mmol/l) 2.68 (0.07) 2.9 (0.19) 0.064
AUC insulin 58.16 (1.43) 69.95 (3.4) 0.003
Peak insulin (mU/l) 56.49 (1.45) 65.14 (3.48) 0.027
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than common allele homozygotes, carriers of both rare
alleles showed TG levels 23% higher than wild type
(P < 0.005) (Fig. 2). The intergenic  12238T>C showed
no significant effect on TG levels but the statistically
significant effects on cholesterol, LDL-cholesterol and apoB
levels were primarily due to the heterozygotes having the
lowest levels. Compared to common  12238T carriers, rare
CC homozygotes had significantly higher waist to hip ratio
(WHR), a measure of obesity (P= 0.0006) and higher
systolic blood pressure (P= 0.012). There was no signifi-
cant interaction between any of the APOA5 variants with
smoking status (not shown).
4.2. APOA5 variants and response to OFTT and OGTT
Both APOA5  1131T>C and S19W had significant
effects on the response to the OFTT (Fig. 3A,B), but these
were no longer statistically significant after adjustment for
fasting TG levels. Neither  1131T>C nor S19W had an
effect on the glucose response to the OGTT. The intergenic
 12238T>C had no effect on postprandial clearance of TG.
However, this variant influenced the response to the OGTT.
Compared to  12238T carriers, homozygotes for the
 12238C allele showed significantly higher AUC insulinand peak insulin levels even after adjustment for fasting
insulin levels (P= 0.003 and P= 0.027, respectively), and
significantly higher AUC glucose with borderline effects on
peak glucose (P= 0.037 and P= 0.063, respectively). Since
there was no heterogeneity between cases and controls, the
data from cases and controls were pooled (Table 4). We
previously showed that of the APOC3 SNPs, the  482C>T
had an effect on glucose and insulin levels after the OGTT
[13]. To test the relative influence of  12238T>C and
APOC3  482C>T on AUC insulin after the glucose load,
their joint effect was examined (Fig. 4). Men homozygous
for both rare alleles (APOA4/A5  12238TT and APOC3
 482TT) had the greatest AUC and peak insulin, and thus
Fig. 4. The combined effects of APOA5  12238T>C and APOC3  482T>C on AUC insulin and peak insulin levels after the OGTT. Data from the cases and
controls are presented separately because of the heterogeneity of the effects.
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response to a glucose challenge.5. Discussion
When examining the influence on quantitative traits of
multiple SNPs in a gene, or gene cluster, the impact of LD
must be taken into account. The observed pattern of strong
LD across the three-gene cluster on chromosome 11q23 was
similar, for the most part, to that reported previously [3].
The APOA5 S19W and the APOC3 3238C>G, at either end
of the three-gene cluster, showed no significant LD in this
study, and appear to define the limits of the LD block.
5.1. APOA5 variants influence fasting TG
There is now strong evidence that variation in APOA5
determines fasting plasma TG levels [1–4], and our data,
examining the effect of these variants in healthy young men
from centres across Europe, ranging from Finland in the
North to Italy in the South, confirm this. In a study of
Japanese children aged between 9 and 13 years, the associ-
ation between the APOA5  1131T>C and plasma lipids
was examined. Even in these young children, the  1131C
allele was associated with significant TG-raising effects,
confirming that variants in APOA5 are major determinants
of plasma TG levels and, taking the EARSII results into
account, this demonstrates that the effect of APOA5 variants
are not confined to adults [14] but exerts its effects in an age-
and diet-independent manner. In our study, both the promoter
( 1131T>C) and signal peptide (S19W) variants were
associated with effects on TG, although these effects were
not as strong as those seen in middle-aged men [3]. These
two variants, on opposite chromosomes as evident from their
negative LD, define two TG-raising haplotypes, APOA5* 2
and APOA5* 3, respectively [4]. Thus, the EARSII results,
showing that the allelic effects of these two variants were
recessive and complementary, confirm the suggestion that
the two rare alleles are on different haplotypes [3,4].
Using 9-SNP haplotype analysis across the cluster, we
previously reported that the haplotypes most strongly asso-
ciated with TG-raising were defined by either the APOA5W19 or APOC3  482T, in combination with other APOC3
SNPs [3]. We have previously reported that in middle-aged
UK men, the APOC3 TG-raising effect is enhanced in
smokers [13]. APOA5 variants showed no genotype–smok-
ing interaction. By contrast, both in the young healthy
EARSII men and in the Japanese children [14] the TG-
raising effect of APOA5 are seen independent of environ-
mental interactions. However, the APOA5 S19W effect on
TG was seen only in those young men with a family history
of CHD, and suggests that this variant may be more
important in these offspring of fathers with an early MI,
who appear predisposed to early CHD, and who already
show subtle signs of insulin resistance [8].
The role of apoAV in lipid metabolism remains to be
elucidated; however, it is clear from mouse models that
apoAV is a key regulator of TG. Human APOA5 transgenic
mice have low TG levels [1] and this effect was confirmed
in adenoviral overexpression of APOA5, where plasma
cholesterol was also lowered [16]. APOA5 knockout mice
have high plasma TG levels, confirming the inverse rela-
tionship of APOA5 and TG [1]. It has been suggested that
apoAV may act as a brake on the transport of TGRL from
the liver [15] and thus variants which cause lower levels of
functional apoAV would be predicted to result in higher
plasma TG levels. The functional studies have not been
performed on the APOA5 variants, but it is possible that
variation in the signal sequence of apoAV (S19W) would
perturb apoAV secretion across the endoplasmic reticulum,
as seen with the APOB signal peptide variant [17]. The
promoter variant  1131T>C is in strong LD with APOA5
 3A>G, [4], raising the possibility that it may itself not be
functional but is acting as a marker for the  3A>G. The
 3A>G change occurs in the ‘Kozak’ sequence in APOA5,
and disruption of this six to eight base pair sequence that
precedes the initiation methionine has been shown in other
genes to severely disrupt ribosomal translation efficiency
[18,19], and this would lead to lower levels of apoAV from
this mRNA.
5.2. APOA5 variants and response to the OFTT
Although both APOA5 variants were associated with
effects on the TG postprandial response to the OFTT, after
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statistically significant. This is not altogether surprising
since unlike apoCIII, which is synthesised both in liver
and intestine, apoAV is synthesised primarily in the liver,
and therefore modest differences in hepatic apoAV expres-
sion would be unlikely to influence postprandial TG levels,
which are mainly due to secretion and metabolism of
intestinal chylomicrons.
5.3. APOA4/A5 intergenic 12283T>C and APOC3
482C>T determine response to the OGTT
We previously showed that the APOC3  482C>T was
associated with an altered response of insulin to the OGTT in
these young men [9]. To test if the association of the
intergenic  12238T>C with AUC insulin after the OGTT
was acting as a marker for the APOC3  482C>T, the com-
bined genotypes were examined. Their effects were additive,
demonstrating that the influence of the  12238T>C on the
response to an OGTT was independent of  482C>T. In
both cases, this effect was recessive, with homozygotes for
the rare alleles showing higher AUC insulin than common
allele carriers. Such a recessive pattern of association would
imply that these effects were biologically important only in
those homozygous for the rare alleles. It is of interest that
APOA5  12238T>C showed a North–South gradient with
the rare allele being more frequent in the South. A similar
trend was seen with the APOA4 T347S, with the highest
frequency of the rare allele being present in the South,
although this did not reach statistical significance [10]. This
is not surprising since these two sites are in strong LD.
However, since the APOA5  12238T>C is associated with
features of the metabolic syndrome, and therefore presum-
ably CAD risk, this is contrary to the CAD risk gradient
across Europe, which is higher in the North and lowest in the
South.
5.4. Men homozygous for the APOA4/A5 intergenic
12238C display other features of the metabolic syndrome
One novel finding of the study is that, compared to those
carrying the common allele,  12238C homozygous men
had significantly higher WHR and blood pressure, in
addition to the higher AUC for insulin and peak insulin.
These parameters are all features of the metabolic syndrome
and suggest that variation at this site is having effects over
and above those of the other APOA5 variants on plasma TG
levels. APOC3  482C>T, which also influences the
response to the OGTT, has been shown to disrupt an
insulin-responsive element within the promoter, releasing
apoCIII from down-regulation by insulin [20]. We previ-
ously suggested that APOC3  482C>T might be affecting
the response to a glucose load by perturbing the balance
between nonesterified free fatty acid (NEFA) and glucose
usage [9]. The mechanism by which  12238T>C, within
the APOA4/A5 intergenic region, influences insulin andglucose levels after a glucose challenge, remains unclear.
It is possible that APOA4/A5  12238T>C is simply acting
as a marker for the APOC3  482C>T, and the two SNPs
show strong LD. However, men homozygous for both rare
alleles had AUC insulin and peak insulin that was higher
than men homozygous for one of these alleles. Furthermore,
homozygosity of the  12238C was associated with higher
WHR and blood pressure, effects that were not seen with the
APOC3 variant. This suggests that APOA4/A5  12238T>C
is itself functional or marking an unidentified functional
change. There is the possibility that there are nuclear factor-
binding sites within the APOA4 and APOA5 intergenic
region and this T>C change could influence one of these.
In conclusion, although the precise function of apoAV in
TG metabolism remains undetermined, these data demon-
strate that variants in APOA5 affect fasting, but not post-
prandial TG levels, and that these effects are independent of
other variants in the cluster. These effects, apparent in these
young healthy men and young children [14], appear to be
context-independent in that they show no interaction with
smoking, age, BMI and exercise (not shown). A novel
aspect of this study is the identification of the influence of
variation in the APOA4/A5 intergenic  12238T>C on
parameters of the metabolic syndrome and this suggests
that variation in this cluster may be important for metabolic
homeostasis. The association of APOA5 variants with fam-
ilial combined hyperlipidemia supports this hypothesis [2].Acknowledgements
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